Medplus Health Services Intrinsic Value
MEDPLUS Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹243.75 | ₹195.00 - ₹292.50 | -70.0% | EPS: ₹18.52, Sector P/E: 12x |
| Book Value Method | asset | ₹725.00 | ₹652.50 - ₹797.50 | -10.8% | Book Value/Share: ₹725.00, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹1625.00 | ₹1462.50 - ₹1787.50 | +100.0% | Revenue/Share: ₹2828.33, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹1625.00 | ₹1462.50 - ₹1787.50 | +100.0% | EBITDA: ₹664.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹2031.25 | ₹1625.00 - ₹2437.50 | +150.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹243.75 | ₹219.38 - ₹268.12 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹243.75 | ₹219.38 - ₹268.12 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| ROE Based Valuation | profitability | ₹1120.00 | ₹1008.00 - ₹1232.00 | +37.8% | ROE: 12.9%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹549.64 | ₹494.68 - ₹604.60 | -32.4% | EPS: ₹18.52, BVPS: ₹725.00 |
Want to compare with current market value? Check MEDPLUS share price latest .
Valuation Comparison Chart
MEDPLUS Intrinsic Value Analysis
What is the intrinsic value of MEDPLUS?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Medplus Health Services (MEDPLUS) is ₹725.00 (median value). With the current market price of ₹812.50, this represents a -10.8% variance from our estimated fair value.
The valuation range spans from ₹243.75 to ₹2031.25, indicating ₹243.75 - ₹2031.25.
Is MEDPLUS undervalued or overvalued?
Based on our multi-method analysis, Medplus Health Services (MEDPLUS) appears to be trading above median value by approximately 10.8%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 1.77 | Industry Standard: 2.0+ | Above 1.5 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 1.93 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 12.9% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 9.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 2.02x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
Related Pages for Medplus Health Services
Additional stock information and data for MEDPLUS
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹540 Cr | ₹381 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹144 Cr | ₹103 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹90 Cr | ₹90 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹170 Cr | ₹-182 Cr | Positive Operating Cash Flow | 6/10 |
| March 2021 | ₹3 Cr | ₹-15 Cr | Positive Operating Cash Flow | 6/10 |